Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors

Miral Sadaria Grandhi, Kelly J. Lafaro, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Although gastroenteropancreatic neuroendocrine tumors are often perceived as being indolent tumors, more than half of the patients will harbor liver metastases at the time of diagnosis. Gastroenteropancreatic neuroendocrine tumors have the potential to be aggressive and resistant to therapy, making the integration of both locoregional and systemic therapy even more critical in the treatment of patients with locally advanced or metastatic lesions. Over the last several years, significant advancements have been made in the surgical treatment, liver-directed therapy, and medical management of gastroenteropancreatic neuroendocrine tumors. While surgical resection is the cornerstone of therapy, cytoreductive surgery, orthotopic liver transplantation, local ablation, and intra-arterial therapy all improve the prognosis of patients suffering with locally advanced or metastatic disease. In addition, great strides have been made in the medical management of gastroenteropancreatic neuroendocrine tumors, particularly with the evolution of novel molecular targeted therapy, such as everolimus and sunitinib. Hence, gastroenteropancreatic neuroendocrine tumor is becoming a disease process requiring more of a multi-disciplinary approach with the integration of both locoregional and systemic therapies for improved outcomes.

Original languageEnglish (US)
Pages (from-to)2273-2282
Number of pages10
JournalJournal of Gastrointestinal Surgery
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Neuroendocrine Tumors
Therapeutics
Molecular Targeted Therapy
Liver
Liver Transplantation
Gastro-enteropancreatic neuroendocrine tumor
Neoplasm Metastasis

Keywords

  • Everolimus
  • Gastroenteropancreatic neuroendocrine tumors
  • Intra-arterial therapy
  • Liver metastases
  • Sunitinib

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. / Grandhi, Miral Sadaria; Lafaro, Kelly J.; Pawlik, Timothy M.

In: Journal of Gastrointestinal Surgery, Vol. 19, No. 12, 01.12.2015, p. 2273-2282.

Research output: Contribution to journalArticle

Grandhi, Miral Sadaria ; Lafaro, Kelly J. ; Pawlik, Timothy M. / Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. In: Journal of Gastrointestinal Surgery. 2015 ; Vol. 19, No. 12. pp. 2273-2282.
@article{bc1ce42601c64868b7193ed543f0ef8c,
title = "Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors",
abstract = "Although gastroenteropancreatic neuroendocrine tumors are often perceived as being indolent tumors, more than half of the patients will harbor liver metastases at the time of diagnosis. Gastroenteropancreatic neuroendocrine tumors have the potential to be aggressive and resistant to therapy, making the integration of both locoregional and systemic therapy even more critical in the treatment of patients with locally advanced or metastatic lesions. Over the last several years, significant advancements have been made in the surgical treatment, liver-directed therapy, and medical management of gastroenteropancreatic neuroendocrine tumors. While surgical resection is the cornerstone of therapy, cytoreductive surgery, orthotopic liver transplantation, local ablation, and intra-arterial therapy all improve the prognosis of patients suffering with locally advanced or metastatic disease. In addition, great strides have been made in the medical management of gastroenteropancreatic neuroendocrine tumors, particularly with the evolution of novel molecular targeted therapy, such as everolimus and sunitinib. Hence, gastroenteropancreatic neuroendocrine tumor is becoming a disease process requiring more of a multi-disciplinary approach with the integration of both locoregional and systemic therapies for improved outcomes.",
keywords = "Everolimus, Gastroenteropancreatic neuroendocrine tumors, Intra-arterial therapy, Liver metastases, Sunitinib",
author = "Grandhi, {Miral Sadaria} and Lafaro, {Kelly J.} and Pawlik, {Timothy M.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11605-015-2931-z",
language = "English (US)",
volume = "19",
pages = "2273--2282",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors

AU - Grandhi, Miral Sadaria

AU - Lafaro, Kelly J.

AU - Pawlik, Timothy M.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Although gastroenteropancreatic neuroendocrine tumors are often perceived as being indolent tumors, more than half of the patients will harbor liver metastases at the time of diagnosis. Gastroenteropancreatic neuroendocrine tumors have the potential to be aggressive and resistant to therapy, making the integration of both locoregional and systemic therapy even more critical in the treatment of patients with locally advanced or metastatic lesions. Over the last several years, significant advancements have been made in the surgical treatment, liver-directed therapy, and medical management of gastroenteropancreatic neuroendocrine tumors. While surgical resection is the cornerstone of therapy, cytoreductive surgery, orthotopic liver transplantation, local ablation, and intra-arterial therapy all improve the prognosis of patients suffering with locally advanced or metastatic disease. In addition, great strides have been made in the medical management of gastroenteropancreatic neuroendocrine tumors, particularly with the evolution of novel molecular targeted therapy, such as everolimus and sunitinib. Hence, gastroenteropancreatic neuroendocrine tumor is becoming a disease process requiring more of a multi-disciplinary approach with the integration of both locoregional and systemic therapies for improved outcomes.

AB - Although gastroenteropancreatic neuroendocrine tumors are often perceived as being indolent tumors, more than half of the patients will harbor liver metastases at the time of diagnosis. Gastroenteropancreatic neuroendocrine tumors have the potential to be aggressive and resistant to therapy, making the integration of both locoregional and systemic therapy even more critical in the treatment of patients with locally advanced or metastatic lesions. Over the last several years, significant advancements have been made in the surgical treatment, liver-directed therapy, and medical management of gastroenteropancreatic neuroendocrine tumors. While surgical resection is the cornerstone of therapy, cytoreductive surgery, orthotopic liver transplantation, local ablation, and intra-arterial therapy all improve the prognosis of patients suffering with locally advanced or metastatic disease. In addition, great strides have been made in the medical management of gastroenteropancreatic neuroendocrine tumors, particularly with the evolution of novel molecular targeted therapy, such as everolimus and sunitinib. Hence, gastroenteropancreatic neuroendocrine tumor is becoming a disease process requiring more of a multi-disciplinary approach with the integration of both locoregional and systemic therapies for improved outcomes.

KW - Everolimus

KW - Gastroenteropancreatic neuroendocrine tumors

KW - Intra-arterial therapy

KW - Liver metastases

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84947023456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947023456&partnerID=8YFLogxK

U2 - 10.1007/s11605-015-2931-z

DO - 10.1007/s11605-015-2931-z

M3 - Article

VL - 19

SP - 2273

EP - 2282

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 12

ER -